Which companies overlap with King Abdullah International Medical Research Center's portfolio?

Top competitors by shared drug class: ALK-Abelló A/S, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., GlaxoSmithKline, Hull University Teaching Hospitals NHS Trust, Il-Yang Pharm. Co., Ltd..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/king-abdullah-international-medical-research-center.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

King Abdullah International Medical Research Center — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

King Abdullah International Medical Research Center pipeline: 3 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Nucleos(t)tide analogues	Nucleos(t)tide analogues	marketed	Nucleos(t)ide reverse transcriptase inhibitor / Nucleos(t)ide polymerase inhibitor	Viral reverse transcriptase; viral polymerase	Virology / Infectious Disease
Nilotinib 300 mg.	Nilotinib 300 mg.	marketed	BCR-ABL tyrosine kinase inhibitor	BCR-ABL	Oncology
low-dose epinephrine and tranexamic acid	low-dose epinephrine and tranexamic acid	marketed	Combination hemostatic and vasopressor agent	Alpha-1 and beta-1 adrenergic receptors (epinephrine); plasminogen and plasmin (tranexamic acid)	Trauma, Hemorrhage, Critical Care
Leukotriene Receptor Antagonist	Leukotriene Receptor Antagonist	phase 3	Leukotriene receptor antagonist	Cysteinyl leukotriene receptors (CysLT1, CysLT2)	Respiratory / Immunology

Therapeutic area mix

Oncology · 1
Respiratory / Immunology · 1
Trauma, Hemorrhage, Critical Care · 1
Virology / Infectious Disease · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

ALK-Abelló A/S · 1 shared drug class
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 shared drug class
GlaxoSmithKline · 1 shared drug class
Hull University Teaching Hospitals NHS Trust · 1 shared drug class
Il-Yang Pharm. Co., Ltd. · 1 shared drug class
Kecioren Education and Training Hospital · 1 shared drug class
Organon and Co · 1 shared drug class
SamA Pharmaceutical Co., Ltd · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for King Abdullah International Medical Research Center:

Cite this brief

Drug Landscape (2026). King Abdullah International Medical Research Center — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/king-abdullah-international-medical-research-center. Accessed 2026-05-17.